A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...

US scientists have decoded why obesity increases the risk of type 2 diabetes by targeting the fat cells.

In a little over two decades, almost 260 million people in the United States are predicted to have overweight or obesity, ...

Without urgent intervention, our study forecasts that more than 80% of adults and close to 60% of adolescents will be ...

Through an analysis of posts on Twitter (now rebranded X) relating to obesity published between April 2019 and December 2022, ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Men with cardiovascular disease risk factors such as type 2 diabetes, obesity, high blood pressure, and smoking may have ...

Sometimes hyped as miracle drugs, even whispered about as elixirs, semaglutide and brand-name variants such as Ozempic and ...

A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 7.4% in premarket trading Tuesday following the release of Phase 2 trial ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...